• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

    7/29/24 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care
    Get the next $PLSE alert in real time by email

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the second quarter 2024 after market close on Monday, August 12, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.

    Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.

    About Pulse Biosciences®

    Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company's proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in Miami, Florida and maintains its office in Hayward, California.

    Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240729277595/en/

    Get the next $PLSE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLSE

    DatePrice TargetRatingAnalyst
    7/7/2025$22.00Outperform
    Oppenheimer
    2/10/2022$43.00 → $20.00Buy
    HC Wainwright & Co.
    11/16/2021$46.00 → $43.00Buy
    HC Wainwright & Co.
    7/27/2021$28.00Overweight
    Stephens & Co.
    More analyst ratings

    $PLSE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2025. Recent Business Highlights Soft Tissue Ablation Expanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation. Treated over 140 Benign Thyroid Nodule patients to date across multiple pilot program centers. Identified five sites to participate in a post-market study of the treatment of benign thyroid disease, with plans to commence enrollment in Q3 upon receipt of IRB approvals. Surgical AF Ablat

    8/12/25 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming 45th Canaccord Genuity Annual Growth Conference in Boston. Pulse Biosciences' Management is scheduled to present on Wednesday, August 13, 2025, at 11:00 am ET. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intenti

    8/1/25 7:00:00 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2025 after market close on Tuesday, August 12, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 or 1-646-307-1963 and providing passcode 2036874. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About

    7/29/25 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $PLSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Duggan Robert W bought $949,298 worth of shares (55,256 units at $17.18), increasing direct ownership by 0.13% to 42,328,717 units (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    12/17/24 8:02:46 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Director Duggan Robert W bought $777,771 worth of shares (45,404 units at $17.13), increasing direct ownership by 0.11% to 42,273,461 units (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    12/17/24 6:05:11 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Director Duggan Robert W bought $972,344 worth of shares (56,054 units at $17.35), increasing direct ownership by 0.13% to 42,228,057 units (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    12/13/24 7:30:48 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $PLSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Principal Accounting Officer Weber Steven

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    7/16/25 6:26:07 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Weber Steven

    3 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    7/16/25 6:21:57 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Chief Technology Officer Uecker Darrin sold $485,700 worth of shares (30,000 units at $16.19), decreasing direct ownership by 20% to 122,872 units (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    6/16/25 8:23:49 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $PLSE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Pulse Biosciences with a new price target

    Oppenheimer initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $22.00

    7/7/25 8:02:36 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $20.00 from $43.00 previously

    2/10/22 6:14:40 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $43.00 from $46.00 previously

    11/16/21 9:11:22 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $PLSE
    SEC Filings

    View All

    SEC Form PRE 14A filed by Pulse Biosciences Inc

    PRE 14A - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    8/18/25 5:20:46 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Pulse Biosciences Inc

    10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    8/12/25 4:17:32 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    8/12/25 4:10:52 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $PLSE
    Leadership Updates

    Live Leadership Updates

    View All

    Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

    Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecon

    2/4/25 8:00:00 AM ET
    $AXTA
    $PLSE
    $TFX
    Paints/Coatings
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

    Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter. "I am inspired by the potential of nano-PFA and the unique catheter

    10/30/24 4:02:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

    Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. "We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical tech

    8/12/24 4:01:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $PLSE
    Financials

    Live finance-specific insights

    View All

    Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2025. Recent Business Highlights Soft Tissue Ablation Expanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation. Treated over 140 Benign Thyroid Nodule patients to date across multiple pilot program centers. Identified five sites to participate in a post-market study of the treatment of benign thyroid disease, with plans to commence enrollment in Q3 upon receipt of IRB approvals. Surgical AF Ablat

    8/12/25 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2025 after market close on Tuesday, August 12, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 or 1-646-307-1963 and providing passcode 2036874. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About

    7/29/25 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2025. Recent Business Highlights Soft Tissue Ablation Expanded direct commercial resources for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025. The Company expects to commence a U.S. clinical trial in mid-2025 to expand evidence for the nsPFA Percutaneous Electrode System as a treatment for benign thyroid nodules. Surgical AF Ablation Received EU approval to expand the clinical protocol for the nsPF

    5/8/25 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $PLSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Pulse Biosciences Inc

    SC 13D/A - PULSE BIOSCIENCES, INC. (0001625101) (Subject)

    7/8/24 3:30:25 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

    SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)

    12/14/23 7:21:15 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

    SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)

    12/4/23 5:18:06 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care